In the phase 1 clinical trials of brenetafusp (IMC-F106C), an ImmTAC bispecific molecule targeting PRAME, for patients with late-line, immune checkpoint pre-treated cutaneous melanoma, the treatment demonstrated promising disease control. The gene discussed is PRAME; the disease is cutaneous melanoma.